The following article is a part of conference coverage from the 2019 Advances in Inflammatory Bowel Diseases (AIBD) Meeting, being held in Orlando, Florida. The team at MPR will be reporting on the latest news and research conducted by leading experts gastroenterology. Check back for more from the 2019 AIBD Meeting..

ORLANDO – An investigational subcutaneous (SC) formulation of vedolizumab may achieve higher rates of maintenance response and remission for the treatment of ulcerative colitis (UC) among responders compared with patients receiving adalimumab SC, according to data from a network meta-analysis presented at the 2019 Advances in Inflammatory Bowel Diseases (AIBD) Annual Meeting, held December 12 to 14, 2019 in Orlando, FL. 

The study authors used results from key randomized-controlled trials (RCTs), which included GEMINI 1, VISIBLE 1, ULTRA 2, and VARSITY, to compare the efficacy and safety of vedolizumab SC vs adalimumab in UC. In the meta-analysis, patients received either adalimumab SC 40mg every 2 weeks, vedolizumab intravenously (IV) 300mg every 4 weeks, vedolizumab IV 300mg every 8 weeks, or vedolizumab SC 108mg every 2 weeks. The efficacy outcomes in the maintenance period were response and remission at 52 weeks in the overall population, as well as anti-tumor necrosis factor (anti-TNF) naive and experienced patients.

Findings from the analysis reported a similar efficacy for vedolizumab IV and SC across all patient populations (eg, anti-TNF naive and experienced subgroups). Similarly, vedolizumab SC demonstrated a higher rate of maintenance response and remission compared to adalimumab, but this was not found to be statistically significant. Regarding safety, vedolizumab SC was associated with a lower risk of overall adverse events.

Study authors concluded, “In the absence of a head-to-head trial between vedolizumab SC and adalimumab SC, these findings support a favorable benefit-risk profile of vedolizumab SC in UC.”

Vedolizumab, an integrin receptor antagonist, is approved for the treatment of moderately-to-severely active UC or CD. The product is available in 20mL single-use vials containing 300mg vedolizumab for intravenous infusion.


Jairath V, Chan K, Lasch K, et al. Comparing the Efficacy and Safety of Subcutaneous Vedolizumab vs Adalimumab for the Treatment of Ulcerative Colitis: A Network Meta-analysis. Presented at: 2019 AIBD Annual Meeting; December 12-14; Orlando, FL.